Aurora Spine Management

Management Kriterienprüfungen 3/4

Aurora Spine CEO ist Trent Northcutt , ernannt in Feb 2012, hat eine Amtszeit von 12.75 Jahren. Die jährliche Gesamtvergütung beträgt $175.23K , bestehend aus 77.8% Gehalt und 22.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 6.8% der Aktien des Unternehmens, im Wert von CA$2.37M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 11.8 Jahre bzw. 11.3 Jahre.

Wichtige Informationen

Trent Northcutt

Geschäftsführender

US$175.2k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	77.8%
Amtszeit als Geschäftsführer	12.8yrs
Eigentum des Geschäftsführers	6.8%
Durchschnittliche Amtszeit des Managements	11.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	11.3yrs

Jüngste Management Updates

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Jun 19

Recent updates

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Jun 19

Is Aurora Spine (CVE:ASG) A Risky Investment?

May 29

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

Mar 19

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Oct 15

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aug 11

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

May 01

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Dec 22

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aug 23

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

May 04

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Dec 23

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Jun 11

A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)

Feb 26

Is Aurora Spine (CVE:ASG) A Risky Investment?

Nov 19

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Trent Northcutt im Vergleich zu den Einnahmen von Aurora Spine verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-US$636k
Jun 30 2024	n/a	n/a	-US$956k
Mar 31 2024	n/a	n/a	-US$1m
Dec 31 2023	US$175k	US$136k	-US$2m
Sep 30 2023	n/a	n/a	-US$2m
Jun 30 2023	n/a	n/a	-US$2m
Mar 31 2023	n/a	n/a	-US$2m
Dec 31 2022	US$123k	US$106k	-US$2m
Sep 30 2022	n/a	n/a	-US$2m
Jun 30 2022	n/a	n/a	-US$2m
Mar 31 2022	n/a	n/a	-US$2m
Dec 31 2021	US$127k	US$111k	-US$2m
Sep 30 2021	n/a	n/a	-US$1m
Jun 30 2021	n/a	n/a	-US$793k
Mar 31 2021	n/a	n/a	-US$58k
Dec 31 2020	US$143k	US$131k	-US$232k
Sep 30 2020	n/a	n/a	-US$777k
Jun 30 2020	n/a	n/a	-US$2m
Mar 31 2020	n/a	n/a	-US$2m
Dec 31 2019	US$143k	US$131k	-US$1m
Sep 30 2019	n/a	n/a	-US$756k
Jun 30 2019	n/a	n/a	-US$199k
Mar 31 2019	n/a	n/a	-US$114k
Dec 31 2018	US$157k	US$125k	-US$68k
Sep 30 2018	n/a	n/a	-US$877k
Jun 30 2018	n/a	n/a	-US$1m
Mar 31 2018	n/a	n/a	-US$2m
Dec 31 2017	US$137k	US$125k	-US$2m

Vergütung im Vergleich zum Markt: TrentDie Gesamtvergütung ($USD175.23K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Canadian ($USD169.25K).

Entschädigung vs. Einkommen: TrentDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Trent Northcutt (57 yo)

12.8yrs

Amtszeit

US$175,227

Vergütung

Mr. Trent J. Northcutt is the Chief Executive Officer and President at Aurora Spine Corporation since February 2012. He is a Founder of Aurora Spine Corporation. Mr. Northcutt served as Vice President at S...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Trent Northcutt	Founder	12.8yrs	US$175.23k	6.8% CA$ 2.4m
Chad Clouse	Chief Financial Officer	4.3yrs	US$168.37k	0.0077% CA$ 2.7k
Laszlo Garamszegi	CTO & Founder	11.8yrs	US$151.07k	keine Daten
David Meyer	VP, Chief Legal Officer & Secretary	no data	US$143.07k	keine Daten
Matthew Goldstone	Chief Commercial Officer	no data	keine Daten	keine Daten

11.8yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: ASGDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (11.8 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Trent Northcutt	Founder	11.3yrs	US$175.23k	6.8% CA$ 2.4m
David Rosenkrantz	Independent Chairman	11.3yrs	keine Daten	15.87% CA$ 5.5m
Tracy Graf	Independent Director	11.3yrs	keine Daten	0.54% CA$ 189.0k
Joseph MacLellan	Independent Director	11.3yrs	keine Daten	0.18% CA$ 64.3k
James Snow	Independent Director	11.3yrs	keine Daten	0.77% CA$ 269.7k
Michael Seid	Independent Director	11.3yrs	keine Daten	0.13% CA$ 43.7k

11.3yrs

Durchschnittliche Betriebszugehörigkeit

59.5yo

Durchschnittliches Alter

Erfahrener Vorstand: ASGDie Vorstandsmitglieder sind sehr erfahren ( 11.3 ).

Aurora Spine Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024

Independent Director recently sold CA$135k worth of stock

Independent Director recently bought CA$105k worth of stock

Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023

Independent Chairman exercised options to buy CA$355k worth of stock.

Recent updates

Third quarter 2024 earnings released

Aurora Spine Corporation (CVE:ASG) Soars 26% But It's A Story Of Risk Vs Reward

We Think Aurora Spine (CVE:ASG) Has A Fair Chunk Of Debt

Aurora Spine Corporation Announces Release of Its Hydra Osteo Onyx Lumbar System

Second quarter 2024 earnings released: US$0.023 loss per share (vs US$0.007 loss in 2Q 2023)

Aurora Spine Corporation's (CVE:ASG) Subdued P/S Might Signal An Opportunity

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Is Aurora Spine (CVE:ASG) A Risky Investment?

Full year 2023 earnings released: US$0.02 loss per share (vs US$0.022 loss in FY 2022)

Aurora Spine Corporation to Report Q1, 2024 Results on May 13, 2024

Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024

New minor risk - Insider selling

Independent Director recently sold CA$135k worth of stock

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

New minor risk - Share price stability

Aurora Spine Corporation to Showcase Sacroiliac Joint (Si Joint) Fusion Products At North American Neuromodulation Society Annual Meeting

Aurora Spine Corporation Announces Newly Published Paper on First 6-Month Clinical Evaluation of its ZIP™? Fusion Implant

Third quarter 2023 earnings released: US$0.004 loss per share (vs US$0.002 loss in 3Q 2022)

Independent Director recently bought CA$105k worth of stock

Aurora Spine Corporation announced that it has received CAD 1.933782 million in funding

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Corporation Announces Full Release of its SiLO TFX™? MIS Sacroiliac Joint Fixation System

Second quarter 2023 earnings released: US$0.01 loss per share (vs US$0.002 loss in 2Q 2022)

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aurora Spine Corporation Announces Initial Patient Enrolled for DEXA-CTM Multicenter Study

Aurora Spine Corporation to Report Q1, 2023 Results on May 24, 2023

Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

Full year 2022 earnings released: US$0.02 loss per share (vs US$0.04 loss in FY 2021)

Independent Chairman exercised options to buy CA$355k worth of stock.

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Third quarter 2022 earnings released: US$0.002 loss per share (vs US$0.007 loss in 3Q 2021)

Aurora Spine Corporation to Report Q3, 2022 Results on Nov 21, 2022

Insufficient new directors

Aurora Spine Corporation Announces Positive Interim Results from Clinical Study Using Zip(TM) MIS Interspinous Fusion System

Aurora Spine Corporation Announces FDA 510(K) Clearance for Its Silo TFX MIS Sacroiliac Joint Fixation System

Second quarter 2022 earnings released: US$0.002 loss per share (vs US$0.013 loss in 2Q 2021)

Aurora Spine Corporation to Report Q2, 2022 Results on Aug 29, 2022

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Announces New FDA Indication Clearance of Lumbar Spinal Stenosis for Its ZIP™ Series of MIS Implants

Aurora Spine Corporation Receives FDA 510(K) Clearance for Its Dexa Solo-LTM Spinal Fusion System

Aurora Spine Corporation to Report Q1, 2022 Results on May 23, 2022

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Full year 2021 earnings released: US$0.04 loss per share (vs US$0.004 loss in FY 2020)

Insufficient new directors

Aurora Spine Corporation Announces Initial Implantation of the First Bone Density Matched DEXA-C Cervical Interbody Fusion Device

Aurora Spine Corporation Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Aurora Spine Corporation Receives Notice of Allowance for Patent for Spinal Implant for Motion Preservation or Fusion

Aurora Spine Corporation Completes First Anterior Cervical Discectomy and Fusion Procedures with its Proprietary APOLLOTM Anterior Cervical Plate

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Aurora Spine Corporation Announces Newly Published Paper on Need for A Bone Mineral Density-Matched Interbody Cage

Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.006 profit in 3Q 2020)

Aurora Spine Corporation Will Showcase Its New FDA-Cleared DEXA-C Anterior Fusion Cages At the North American Spine Society Annual Meeting

Aurora Spine Corporation announced that it has received CAD 6.508139 million in funding

Second quarter 2021 earnings released: US$0.01 loss per share (vs US$0.001 profit in 2Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Announces First Patients in Multicenter Study of ZIP® Interspinous Fixation Device

Aurora Spine Corporation Announces FDA 510(K) Clearance for DEXA-C Cervical Interbody System

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

First quarter 2021 earnings released: US$0.01 loss per share (vs US$0.011 loss in 1Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Receives Irb Approval to Commence Registration for Multicenter Study of Its Silo™ Device for Si Joint Pain

Full year 2020 earnings released

Aurora Spine Corporation Announces Launch of its SiLOTM Posterior SI Joint Fusion System

A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)

New 90-day high: CA$0.53

Aurora Spine Corporation(TSXV:ASG) dropped from S&P/TSX Venture Composite Index

New 90-day high: CA$0.44

New 90-day high: CA$0.38